BC Cancer Agency's GSC Installs 8 More SOLiDs for Cancer Genome Projects; Also Plans Illumina Expansion | GenomeWeb

By Julia Karow

This story has been updated to reflect that the GSC purchased a total of 10 SOLiD systems, including two it received last summer for evaluation, and to add comments from Life Technologies.

The Genome Sciences Centre of the British Columbia Cancer Agency in Vancouver has installed eight additional Applied Biosystems SOLiD 3 Plus instruments, adding to its existing fleet of 14 Illumina Genome Analyzers IIx, two SOLiD 3 Plus, and eight 3730 Sanger sequencers.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.